Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • TA137
  • Published: 
Download guidance (PDF)

1 Guidance

This guidance replaces 'The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma' (NICE technology appraisal guidance 37 issued in March 2002).

For details, see 'About this guidance'.

1.1 Rituximab, within its marketing authorisation, in combination with chemotherapy, is recommended as an option for the induction of remission in people with relapsed stage III or IV follicular non-Hodgkin's lymphoma.

1.2 Rituximab monotherapy as maintenance therapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed stage III or IV follicular non-Hodgkin's lymphoma in remission induced with chemotherapy with or without rituximab.

1.3 Rituximab monotherapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).